New investors in gene therapy have missed the boat—the goose's golden eggs are gone

Share prices set to tumble...wonderful news, take heart!

Sep 21, 2023

∙ Paid

Gene therapy has been a flop

In the post below, I predicted gene therapy products would be a flop once the shine wore off. Then, not too long ago, we heard the world’s largest contract development and manufacturing organisation (CDMO), Lonza, had fired its CEO on the back of reduced company earnings. Lonza manufactures the Moderna jab active ingredient, as those paying attention will know :O). Lonza’s share price dropped by 8% on the news!

Pharma investors—gene therapy is not the golden goose you think it is

Hedley Rees

August 11, 2022

Pharma investors—gene therapy is not the golden goose you think it is

INSIDE PHARMA is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber. Investors piling into gene therapy In May, I posted about the need for investors to be wary about the profit potential for pharmaceutical products based on gene therapy. It refers to an article penned by me and Daniel O’C…

Read full story

This news was covered by TrialSite News, in an article titled:

Lonza Ousts CEO? He Made Big Bets on Moderna/mRNA COVID-19 Vax, Waning Demand in Supply Chain?

This is an extract, where I got to have a say:

“Biotech supply chain expert Hedley Rees, a TrialSite contributor cautioned that the shakeup at Lonza is likely just the tip of the iceberg.

Keep reading with a 7-day free trial

Subscribe to INSIDE PHARMA to keep reading this post and get 7 days of free access to the full post archives.